ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership

News
Article

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

An image of an eye behind glasses. Digital input on the glasses conveys concept of artificial intelligence and computing. Image credit: ©Arsenii – stock.adobe.com

At the ARVO meeting, Zeiss will spotlight its ongoing research collaboration with Boehringer Ingelheim and its new research platform. Image credit: ©Arsenii – stock.adobe.com

Carl Zeiss Meditec AG has introduced its new Zeiss Research Data Platform (ZEISS RDP), a cloud-based, AI-driven solution designed to transform ophthalmic research workflows. A full introduction will be conducted at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting.

Euan S. Thomson, PhD, head of the digital business unit for Zeiss Medical Technology, commented on ZEISS RDP in a press release from the company ahead of ARVO.1

"The future of healthcare is in the data. At Zeiss, we are delivering digital innovation to help shape the future of ophthalmology, investing in research methods that empower clinicians and researchers in balancing their clinical care and research requirements," said Thomson. "The introduction of the ZEISS RDP reflects our commitment to advancing ophthalmic care through smarter, AI-powered tools."

The ZEISS RDP “enables seamless integration of clinical and research data and empowers clinicians and scientists to accelerate discoveries through smarter, more efficient research.”

At the ARVO meeting, Zeiss will also spotlight its ongoing research collaboration with Boehringer Ingelheim, which focuses on precise, personalised ophthalmic interventions. Two expert talks at the Zeiss booth during ARVO will share insights on applications of artificial intelligence in the near future.

"At Boehringer Ingelheim, we’re working toward a future in which earlier detection and intervention result in long-term, real-world outcomes that prevent vision loss due to chronic retinal diseases," said Heiko G. Niessen, PhD, global head of translational medicine, eye health, at Boehringer Ingelheim. "Our collaboration with ZEISS Medical Technology exemplifies our strategy to work with like-minded partners who share our goal of preserving and protecting eyesight and people’s way of life."

Attributes of the ZEISS RDP include the ability for clinicians and researchers to convert their research hypotheses into quantifiable biomarkers and to train their own algorithms and let AI handle complex, time-consuming data analysis, significantly improving efficiency.

The platform will also allow users to aggregate diverse datasets and formats from multiple sources and allow for a more “streamlined research workflow.”

Following a successful pilot phase, the company plans to launch the ZEISS RDP in select countries throughout 2025.

References:

  1. ZEISS unveils AI-powered research data platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care. Published May 1, 2025. Accessed May 1, 2025. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2025/research-data-platform.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.